Incyte Biosciences Japan GK clinical trials
A country office of Incyte Corporation
The registry lists 6 studies whose lead sponsor is Incyte Biosciences Japan GK. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Registry sponsor names on this page
- Incyte Biosciences Japan GK6 studies
Something wrong with this grouping? Tell us on the Incyte Corporation page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Incyte Corporation studies →
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2
Sponsor listed in the registry: Incyte Biosciences Japan GK
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06263478Phase 3
Sponsor listed in the registry: Incyte Biosciences Japan GK
- To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550TerminatedNCT04674748Phase 1
Sponsor listed in the registry: Incyte Biosciences Japan GK
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedNCT04434937Phase 2
Sponsor listed in the registry: Incyte Biosciences Japan GK
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707CompletedNCT05068466Phase 1
Sponsor listed in the registry: Incyte Biosciences Japan GK
- A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid TumorsCompletedNCT03910530Phase 1
Sponsor listed in the registry: Incyte Biosciences Japan GK